Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fumio Nagashima

Showing results (1-10 of 105) with videos related to

Pageof 11
Sort By:
Expert Review of Gastroenterology & Hepatology|September 14, 2011
Inhibitor of MEK1/2, selumetinib, for biliary tract cancerJunji Furuse, Fumio Nagashima
Chinese Clinical Oncology|April 6, 2015
Current status and future direction of chemotherapy for pancreatic cancerJunji Furuse, Fumio Nagashima
International Journal of Clinical Oncology|January 31, 2022
Treatments for elderly cancer patients and reforms to social security systems in JapanFumio Nagashima, Junji Furuse
Internal Medicine (Tokyo, Japan)|August 20, 2003
Idiopathic granulomatous gastritis with multiple aphthoid ulcersShohei Koyama, Fumio Nagashima
Expert Opinion on Emerging Drugs|March 4, 2017
Emerging protein kinase inhibitors for treating pancreatic cancerJunji Furuse, Fumio Nagashima
Nihon Rinsho. Japanese Journal of Clinical Medicine|April 11, 2015
[Systemic chemotherapy for unresectable pancreatic cancer]Daisuke Naruge, Fumio Nagashima, Junji Furuse
Gan to Kagaku Ryoho. Cancer & Chemotherapy|January 20, 2022
[Oncology in Super-Aged Society]Fumio Nagashima, Kentaro Enomoto, Junji Furuse
Gan to Kagaku Ryoho. Cancer & Chemotherapy|January 19, 2015
[Activity of the JCOG geriatric study committee and chemotherapy of colorectal cancer in older patients]Fumio Nagashima, Tetsuya Hamaguchi, Junji Furuse
Nihon Rinsho. Japanese Journal of Clinical Medicine|April 11, 2015
[Current status and future perspective of chemotherapy for gallbladder cancer]Naohiro Okano, Fumio Nagashima, Junji Furuse
The Lancet. Oncology|September 30, 2021
Stereotactic body radiotherapy plus pembrolizumab and trametinib for pancreatic cancerNaohiro Okano, Tomonori Mizutani, Fumio Nagashima, et al.
Pageof 11

Showing results (1-10 of 105) with videos related to

Sort By:
Pageof 11
Expert Review of Gastroenterology & Hepatology|September 14, 2011
Inhibitor of MEK1/2, selumetinib, for biliary tract cancerJunji Furuse, Fumio Nagashima
Chinese Clinical Oncology|April 6, 2015
Current status and future direction of chemotherapy for pancreatic cancerJunji Furuse, Fumio Nagashima
International Journal of Clinical Oncology|January 31, 2022
Treatments for elderly cancer patients and reforms to social security systems in JapanFumio Nagashima, Junji Furuse
Internal Medicine (Tokyo, Japan)|August 20, 2003
Idiopathic granulomatous gastritis with multiple aphthoid ulcersShohei Koyama, Fumio Nagashima
Expert Opinion on Emerging Drugs|March 4, 2017
Emerging protein kinase inhibitors for treating pancreatic cancerJunji Furuse, Fumio Nagashima
Nihon Rinsho. Japanese Journal of Clinical Medicine|April 11, 2015
[Systemic chemotherapy for unresectable pancreatic cancer]Daisuke Naruge, Fumio Nagashima, Junji Furuse
Gan to Kagaku Ryoho. Cancer & Chemotherapy|January 20, 2022
[Oncology in Super-Aged Society]Fumio Nagashima, Kentaro Enomoto, Junji Furuse
Gan to Kagaku Ryoho. Cancer & Chemotherapy|January 19, 2015
[Activity of the JCOG geriatric study committee and chemotherapy of colorectal cancer in older patients]Fumio Nagashima, Tetsuya Hamaguchi, Junji Furuse
Nihon Rinsho. Japanese Journal of Clinical Medicine|April 11, 2015
[Current status and future perspective of chemotherapy for gallbladder cancer]Naohiro Okano, Fumio Nagashima, Junji Furuse
The Lancet. Oncology|September 30, 2021
Stereotactic body radiotherapy plus pembrolizumab and trametinib for pancreatic cancerNaohiro Okano, Tomonori Mizutani, Fumio Nagashima, et al.
Pageof 11